title: Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis?
authors.affiliation: Department of Interventional Cardiology, San Raffaele Scientific Institute, Milan, Italy; Department of Interventional Cardiology, EMO-GVM Centro Cuore Columbus, Milan, Italy. Electronic address: info@emocolumbus.it.
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.affiliation: Department of Interventional Cardiology, San Raffaele Scientific Institute, Milan, Italy; Department of Interventional Cardiology, EMO-GVM Centro Cuore Columbus, Milan, Italy; Department of Cardiology, Imperial College, London, United Kingdom.
authors.forename: Neil
authors.initials: N
authors.lastname: Ruparelia
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus
keywords: drug-eluting balloon; drug-eluting stent(s); in-stent restenosis; percutaneous coronary intervention